Yao HP - Search Results

1

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.

Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP. Weng TH, et al. Among authors: yao my, yao hp, yao sh. Cancer Res Treat. 2020 Jul;52(3):973-986. doi: 10.4143/crt.2019.726. Epub 2020 Apr 22. Cancer Res Treat. 2020. PMID: 32324988 Free PMC article.

2

Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.

Wang MH, Yao HP, Zhou YQ. Wang MH, et al. Among authors: yao hp. Acta Pharmacol Sin. 2006 Jun;27(6):641-50. doi: 10.1111/j.1745-7254.2006.00361.x. Acta Pharmacol Sin. 2006. PMID: 16723080 Review.

3

Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.

Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH. Yao HP, et al. Cancer Biol Ther. 2006 Sep;5(9):1179-86. doi: 10.4161/cbt.5.9.3073. Epub 2006 Sep 11. Cancer Biol Ther. 2006. PMID: 16880737 Free article.

4

Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.

Wang MH, Lao WF, Wang D, Luo YL, Yao HP. Wang MH, et al. Among authors: yao hp. Cancer Biol Ther. 2007 Jul;6(7):1121-9. doi: 10.4161/cbt.6.7.4337. Cancer Biol Ther. 2007. PMID: 17611409 Free article.

5

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

Lu Y, Yao HP, Wang MH. Lu Y, et al. Among authors: yao hp. Cancer Lett. 2007 Nov 18;257(2):157-64. doi: 10.1016/j.canlet.2007.08.007. Epub 2007 Sep 21. Cancer Lett. 2007. PMID: 17889431 Review.

6

Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.

Zhang K, Yao HP, Wang MH. Zhang K, et al. Among authors: yao hp. Carcinogenesis. 2008 Mar;29(3):552-9. doi: 10.1093/carcin/bgn003. Epub 2008 Jan 19. Carcinogenesis. 2008. PMID: 18204077

7

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.

Lu Y, Yao HP, Wang MH. Lu Y, et al. Among authors: yao hp. J Exp Clin Cancer Res. 2008 Oct 25;27(1):55. doi: 10.1186/1756-9966-27-55. J Exp Clin Cancer Res. 2008. PMID: 18950514 Free PMC article.

8

Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.

Zhang K, Zhou YQ, Yao HP, Wang MH. Zhang K, et al. Among authors: yao hp. Int J Oncol. 2010 Jan;36(1):255-64. Int J Oncol. 2010. PMID: 19956854

9

RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.

Guin S, Yao HP, Wang MH. Guin S, et al. Among authors: yao hp. Mol Pharm. 2010 Apr 5;7(2):386-97. doi: 10.1021/mp900168v. Mol Pharm. 2010. PMID: 20039696

10

Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.

Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S, Wang MH. Ma Q, et al. Among authors: yao hp. Int J Oncol. 2010 Jun;36(6):1551-61. doi: 10.3892/ijo_00000642. Int J Oncol. 2010. PMID: 20428780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters